drugset

drugset / Trial / NCT04821375

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

NCT04821375 ↗

Phase 0 Completed 16 enrolled Carol Fabian, MD

RandomizedParallel-groupOpen-labelPrevention

Summary

Pilot study to test feasibility of 6 months of bazedoxifene (BZA) plus conjugated estrogens (CE) to modulate breast MRI parameters.

Timeline

Start: 2021-12-02
Primary completion: 2024-05-20
Completion: 2024-12-31

Publications

Background Fabian CJ, Nye L, Powers KR, Nydegger JL, Kreutzjans AL, Phillips TA, Metheny T, Winblad O, Zalles CM, Hagan CR, Goodman ML, Gajewski BJ, Koestler DC, Chalise P, Kimler BF. Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study. Cancer Prev Res (Phila). 2019 Oct;12(10):711-720. doi: 10.1158/1940-6207.CAPR-19-0315. Epub 2019 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bazedoxifene	Other / unclassified	20 mg	—
Subject	conjugated estrogens	Other / unclassified	0.45 mg	—

Indications

No indication recorded.